Fentanyl News and Research

RSS

Fentanyl is a powerful synthetic opiate analgesic similar to but more potent than morphine. It is typically used to treat patients with severe pain, or to manage pain after surgery. It is also sometimes used to treat people with chronic pain who are physically tolerant to opiates. It is a schedule II prescription drug.

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study

Butrans (Buprenorphine) Transdermal System CIII 20 mcg/hour provided significantly lower "average pain over the last 24 hours" scores compared to Butrans 5 mcg/hour when used in opioid-experienced patients with moderate-to-severe chronic low back pain, according to a pivotal Phase 3 clinical study published in the online, August issue of The Journal of Pain.

26 Sep 2011

Study: Opioid drugs can increase risk of pneumonia in older adults

Opioids -- a class of medicines commonly given for pain -- were associated with a higher risk of pneumonia in a study of 3,061 adults, aged 65 to 94, e-published in advance of publication in the Journal of the American Geriatrics Society.

23 Sep 2011

Drug overdose deaths surpass road traffic accident deaths in U.S.

According to newly released figures, drug-related deaths now outnumber traffic fatalities in the U.S., with the rise driven by an increase in prescription narcotic overdoses.

19 Sep 2011

Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence

BioDelivery Sciences International, Inc. announced positive preliminary results from its Phase 1 study assessing the pharmacokinetics of a BEMA Buprenorphine/Naloxone formulation.

6 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

New Pressurized Olfactory Device shows direct CNS effect of morphine

A simple new approach to nasal drug administration may allow morphine and other strong pain medications to be targeted directly to the central nervous system (CNS), reports an experimental study in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Aug 2011

Orexo reports net revenues of MSEK 55.2 for second quarter 2011

OREXO: STRONG SALES INCREASE FOR ABSTRAL. For the period. Royalty revenues from Abstral sales in Europe rose to MSEK 30.4.

10 Aug 2011

Akela announces new corporate focus on PharmaForm

Akela Pharma, Inc. today announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC.

9 Aug 2011

Covidien third quarter net sales increase 14% to $2.93 billion

Covidien plc today reported results for the third quarter of fiscal 2011. Net sales of $2.93 billion increased 14% from the $2.56 billion reported in the third quarter a year ago.

26 Jul 2011

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BioDelivery Sciences International, Inc. announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.

25 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Akela reports total consolidated revenues of $4.2 million for three months ended March 31, 2011

Akela Pharma, Inc., a drug development company with its lead product, Fentanyl TAIFUN, being developed for the treatment of breakthrough cancer pain and the company's wholly owned subsidiary, PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three months and year ended March 31, 2011.

15 Jun 2011

FDA accepts Insys NDA for Fentanyl SL Spray to treat breakthrough cancer pain

Insys Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.

12 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

Facts become greatest casualty in war on pain medications

The Florida Society of Pain Management Providers urges Government, Law Enforcement and the media to stop using false prescription drug data and statistics. The continued release of false and / or out of context information is solely intended to enflame the public. The misinformation that unfairly portrays Florida as ground zero in this issue has significant consequences for pain management patients and the physicians who provide legitimate care.

22 Apr 2011

Covidien second quarter net sales up 10% to $2.80 billion

Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.

21 Apr 2011

Orexo partner ProStrakan launches Abstral in the US

Orexo AB announces today that its partner ProStrakan Group plc has launched Abstral in the United States.

4 Apr 2011

Akela reports net income of $1.5 million for three months ended December 31, 2010

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months and year ended December 31, 2010.

1 Apr 2011